Evidence map›Paper›PMID 29161986›Full record

ArticleThyroid : official journal of the American Thyroid Association2018

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Priyanka C Iyer, Ramona Dadu, Renata Ferrarotto, Naifa L Busaidy, Mouhammed A Habra, Mark Zafereo, Neil Gross, Kenneth R Hess, Maria Gule-Monroe, Michelle D Williams and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thyroid : official journal of the American Thyroid Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 4 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 4 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2021
    Guideline
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Predicting overall survival in anaplastic thyroid cancer using machine learning approaches.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
  17. Review
  18. VSIG4Journal of experimental & clinical cancer research : CR · 2025
    Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Priyanka C Iyer1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Ramona Dadu1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Renata Ferrarotto3 Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Naifa L Busaidy1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Mouhammed A Habra1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Mark Zafereo4 Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Neil Gross4 Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Kenneth R Hess5 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Maria Gule-Monroe6 Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Michelle D Williams7 Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center , Houston, Texas.
Maria E Cabanillas1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center , Houston, Texas.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial.

methodsThis is a retrospective review from April 2015 to May 2016 at a single academic institution where 16 ATC patients receiving targeted therapy outside of a clinical trial were studied. Ten patients (eight BRAF wild type and two BRAF

resultsThe majority of patients (63%) were men, and all had distant metastases or radiation-resistant primary disease at the time of treatment. In the entire cohort, 6/16 (38%) had a partial response, 6/16 (38%) had stable disease, and 2/16 (12%) had progressive disease. Two (12%) patients died before restaging. Median follow-up time was 11.8 months. Median progression-free survival was 3.7 months [confidence interval 1.8-7.6] in the entire cohort, 2.7 months for lenvatinib, and 5.2 months for dabrafenib plus trametinib. Median OS was 6.3 months [confidence interval 1.8-7.6] for the entire cohort, 3.9 months for lenvatinib, and 9.3 months for dabrafenib plus trametinib. Adverse events were as expected and manageable.

conclusionsTargeted therapies, lenvatinib, and dabrafenib plus trametinib (for BRAF

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImidazolesMaleMiddle AgedMutationOximesPhenylurea CompoundsPrognosisProgression-Free SurvivalProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAF protein, humandabrafenibImidazoleslenvatinibOximesPhenylurea CompoundsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesQuinolinestrametinibchemotherapydabrafeniblenvatinibthyroid cancertrametinibundifferentiated

Identifiers

PMID29161986
PMCPMC6425981
OpenAlexW2769724680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.